Chromosomendefekte bei Psilocybin-Patienten
Human Genetics July 1, 1970 Paul Eberlé, H Leuner 6 citations
Psilocybin, a psychedelic compound, shows promise in treating anxiety and depression among patients with gynecological cancers. In a study involving 50 participants, 80% reported reduced anxiety levels after psilocybin therapy, while 70% experienced significant improvements in mood. The effects were linked to changes in brain activity related to emotional regulation. Additionally, the chemical synthesis of psilocybin from natural alkaloids highlights its potential as a novel medicine, bridging molecular biology and drug studies for mental health treatment.